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Summary
Objectives: The presently advocated tests for rapid diagnosis of rabies, such as the
fluorescent antibody test (FAT) are expensive and require expertise to carry out and
interpret the results. In this study, a simple direct dot blot enzyme immunoassay (DIA)
has been developed and evaluated to detect the rabies antigen in brain specimens of
animals and humans. The utility of this test in the ante-mortem diagnosis of human
rabies has also been evaluated.
Methods: Brain homogenates of suspected rabid animals (n = 250), humans (n = 16)
and clinical samples like saliva (n = 12) and cerebrospinal fluid (CSF) (n = 12) were
directly spotted on polyvinylidene difluoride membrane (PVDF) and the absorbed
rabies nucleoprotein antigen was detected using biotinylated antinucleoprotein
antibody followed by treatment with streptavidin peroxidase conjugate and color
development with diamino benzedine (DAB). Rabies-infected and normal mouse brain
homogenates were used as positive and negative controls, respectively. The results of
this test were evaluated with fluorescent antibody technique (for brain samples) and
mouse inoculation test (for saliva and CSF samples).
Results: A distinct dark brown color was seen in the positive control and all positive
samples, while therewas no color development with either the negative control or the
negative samples. The concordance between the fluorescent antibody test (FAT) and
dot immunoassay was 98.4% for brain samples, 83.3% for saliva and 91.6% for CSF
samples. The specificity of the test was found to be 100%.* Corresponding author. Tel.: +91 80 699 5128/5129; fax: +91 80 656 4830.
E-mail address: mshampur@hotmail.com (S.N. Madhusudana).
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340 S.N. Madhusudana et al.Conclusions: The dot blot enzyme immunoassay (DIA) test described here is a
sensitive, specific and rapid test for the post-mortem diagnosis of rabies in animals
and humans. The utility of this test for the ante-mortem diagnosis of rabies needs to
be further evaluated.
# 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Human and animal rabies continues to be a signifi-
cant public health problem in many Asian, South
American and African countries. According to the
latest report from the World Health Organization,
about 50,000 human deaths are reported worldwide
every year andmore than 80% of these cases occur in
Asian countries.1 India alone accounts for 30,000
human deaths per year.
Although human rabies has been eliminated or
controlled to a great extent in North America and
Europe, rabies in wild animals and bats poses a sig-
nificant threat to human populations in these regions.
The Australian continent, which was hitherto consid-
ered rabies free, has recently reported a rabies-like
disease in humans caused by exposure to bats.2 As the
rabies virus persists in many animal reservoirs, it may
not be possible to eliminate human rabies in the near
future. Although human rabies is virtually 100% fatal,
it is effectively preventable if state of the art pro-
phylactic measures are instituted, particularly in
people exposed to bites from proven rabid animals.
Laboratory confirmation of the rabid status of the
biting animal becomes important considering the fact
that rabies vaccines and immunoglobulins are very
expensive and are always in short supply. In countries
like India,more than threemillionpeopleper year are
exposed to dog bites and require post-exposure treat-
ment, with a consequential burden on the govern-
ment finances.3 However, the majority of these
exposures are to animals which later turn out to be
normal and healthy. Post-exposure treatment with
these expensive biologicals can be avoided once the
diagnosis of rabies is ruled out by approved laboratory
tests using a brain specimen of the biting animal.
Many tests have been used for the diagnosis of
rabies, including detection of Negri bodies, the
fluorescent antibody test, the infection of neuro-
blastoma cells, mouse inoculation and the recently
developed enzyme immunoassays and molecular
methods.4 However, with the exception of the
demonstration of Negri bodies, all other tests
require considerable expertise and expensive equip-
ment and are generally only carried out in reference
laboratories. Diagnosis based purely on Negri body
demonstration may be erroneous, as both falsenegatives and false positives are frequently
observed.5
There is therefore a need to develop a simple and
economical test for the diagnosis of rabies which can
be routinely used in peripheral centers under field
conditions without compromizing on specificity and
sensitivity. These tests should also assist in the rapid
confirmation of rabies in patients presenting with
atypical clinical features. Detection of viral anti-
gens by enzyme immunoassays using reagents
blotted on to nitrocellulose or other membranes is
not a new technique in diagnostic virology.6—8 How-
ever, use of this procedure in rabies diagnosis has
not found wide application. Keeping this in view,
this paper describes the development and evalua-
tion of a direct dot blot enzyme immunoassay (DIA)
for detection of the rabies antigen in autopsied
brain tissues and clinical samples. The results indi-
cate a very high level of correlation with the gold
standard technique — fluorescent antibody test
(FAT) — and this new test may serve as an econom-
ical alternative that can be used routinely under
field conditions, not only for diagnosis but also for
epidemiological surveys. This test may also be use-
ful for the ante-mortem diagnosis of human rabies.Materials and methods
Brain samples
A total of 266brain samples (250 from suspect animals
and 16 from humans) were included in this study. The
specimens from animals (portions of Ammon’s horn
and cerebral cortex) were sent to the laboratory
preserved in 50% glycerol saline. Of these, 210 sam-
ples were from dogs, 30were from cattle and 10 from
cats. Sixteen human brains were also sampled. These
were taken fresh after autopsy on patients admitted
to the neurological services department of the
National Institute of Mental Health and Neuroscience
(NIMHANS) and suspected to have died of rabies.
Clinical samples
Cerebrospinal fluid (CSF) and saliva samples of these
same patients taken ante-mortem between the
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75 8Cwere also included. Thesewere tested by dot
immunoassay to determine if this test could be used
for the ante-mortem diagnosis of human rabies.
Preparation of polyclonal antinucleoprotein
antibody and its biotinylation
The rabies nucleoprotein was purified from infected
Vero cells (ATCC CCL, 81 obtained from National
Centre for Cell Science, Pune, India) using standard
procedures described earlier.9 Briefly, confluent
Vero cell monolayers in Roux bottles were infected
with Vero cell adapted CVS 11 strain of the rabies
virus (obtained from Central Research Institute,
Kasauli, India). After 72 hours incubation at 33 8C,
the cells were scraped, suspended in sterile phos-
phate buffer saline at pH 7.2 (PBS) and centrifuged
at 20,000  g. The pellet was resuspended in an
equal volume of sterile distilled water and was
homogenized using a glass Dounze homogenizer.
The material was again centrifuged and the clear
supernatant was collected. This supernatant was
subjected to ultracentrifugation at 150,000  g in
a cesium chloride gradient using a Sorvall Discovery
100 S ultracentrifuge for 18 hours. The clearly visi-
ble rabies nucleocapsid band was collected by side
puncture of the tube and was dialyzed overnight
against PBS. The protein content was determined by
Lowry’s method and purity was confirmed by SDS
PAGE, which showed a single band at 57 Kda.
A female New Zealand rabbit (2.5 kgs) was immu-
nized with this protein. Before immunizing the ani-
mal, permission was obtained from the institutional
animal ethics committee and the animal was housed
and maintained as per the regulations in force. The
first dose consisted of 400 mg of protein mixed with
an equal volume of complete Freund’s adjuvant.
The subsequent doses were given at fortnightly
intervals but mixed with incomplete adjuvant.
The antibody titers were checked by indirect immu-
noflourescence one week after the fourth dose.
When the antibody titer was found to be
1:100,000, the rabbit blood was collected by intra-
cardiac puncture after a light ether anesthesia. The
serum was separated and the IgG was purified by
ammonium sulfate precipitation. The protein con-
tent was determined by Lowry’s method. The anti-
nucleoprotein globulin was biotinylated using
standard procedure10 using biotinamide N hydroxy
succinamide (Sigma, USA. Cat No. B 2643).
Dot blot enzyme immunoassay
The assay was performed using a polyvinylidene
difluoride membrane (Biotrace PVDF, GelmanSciences, USA, Cat No. 8343). The PVDF membrane
was cut into the appropriate size and markings of 1
 1 cmweremadewith a pencil. Themembranewas
then put in a plastic tray and treated with 100%
methanol for five minutes in the dark. The mem-
brane was stabilized for 30 minutes with a buffer
(Tris base 5.8 g, glycine 2.9 g, methanol 200 ml and
the volume made up to 1 litre using milli-Q water).
Before testing the actual samples, the procedure
was standardized using 10% homogenate (in PBS) of
rabies-infected mouse brains and normal mouse
brains. A distinct dark brown spot developed with
rabid mouse brain suspension and there was no color
development with normal mouse brain suspension.
Subsequently these were used as positive and nega-
tive controls for all future tests.
The test brains (portions of Ammon’s horn and
cerebral cortex) were homogenized (10% in sterile
PBS); centrifuged and 3 ml of the clear supernatant
was directly applied as a spot on the membrane. The
saliva and CSF samples were also applied in a similar
manner. For testing these samples, six saliva sam-
ples and six CSF samples taken from apparently
normal healthy people (not having a previous history
of animal bite or rabies vaccination) were also used.
The membrane was left at room temperature in a
moist chamber for one hour and submerged for
30 minutes in a blocking solution containing 3%
skimmed milk powder and 1% normal goat serum
in PBS. The membrane was later rinsed three times
with PBS and air dried. To each spot of the test
material, 3 ml of biotinylated anti-ribonucleopro-
tein (RNP) antibody was added at a predetermined
dilution of 1:500. The membrane was left at room
temperature for one hour under moist conditions
and washed three times with PBS Tween 20 (PBST).
To each spot, 5 ml of streptavidin peroxidase (Sigma,
USA, Cat No. S 9420, 1:15,000 dilution) was added
and kept at room temperature for 30 minutes. After
washing three times with PBST, freshly prepared
diamino benzidine (DAB, 0.04% in PBS with hydrogen
peroxide 0.1%) was added and themembrane kept in
the dark for ten minutes. The reaction was termi-
nated using tap water. A distinct dark-brown colored
spot was observed with the positive control and all
positive brain samples. There was no color observed
with the negative control and negative brain sam-
ples (Figure 1).
Fluorescent antibody test (FAT)
This was performed as per the standard procedure
advocated by the World Health Organization.11 The
rabies FITC conjugate was obtained from the Cen-
tral Research Institute, Kasauli (India). For carrying
out the FAT, smears were obtained from cut portions
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tissues. The stained slides were observed for fluor-
escence using a Leitz Diaplan fluorescence micro-
scope.
Mouse inoculation test (MIT)
For detection of the rabies virus in clinical samples
like CSF and saliva, the mouse inoculation test12 was
performed using litters of two to three-day-old
suckling mice. Permission was obtained from the
institutional ethics committee for use and experi-
mentation on animals. The CSF samples were inocu-
lated without any pretreatment with antibiotics but
saliva samples were pretreated with gentamicin.
The inoculated mice, along with their mothers,
were housed and maintained as per regulations in
force and observed for 30 days. The rabies infection
in the mice developing sickness was confirmed by
carrying out a direct FAT on their extracted brains.Results
Post-mortem brain samples
A total of 266 brain samples were tested by FATand
the same samples were also tested by DIA. The
comparative results of these tests are given in Table
1. It can be seen that the concordance between DIA
and FAT varied from 96.6 to 100%, depending on the
animal species, and the overall concordance was
98.4%. The variation observed probably reflects the
stage of illness during which the brain sample was
obtained rather than a species difference. The
animal brains where DIA was negative but FAT posi-
tive had a very scant distribution of viral antigenTable 1 Results of dot immunoassay on animal and human
Brain samples DIA+ FAT+ DIA FAT
Dog brain (n = 210) 120/210 87/210
Cat brain (n = 10) 5/10 5/10
Cattle (n = 30) 16/30 13/30
Human (n = 16) 12/16 4/16
Total (n = 266) 153/266 109/266
DIA = dot immunoassay; FAT = fluorescent antibody test.
Table 2 Results of dot blot enzyme immunoassay and mo
samples.
Clinical sample DIA+ MIT+ DIA MIT
Saliva (n = 12) 4/12 6/12
CSF (n = 12) 5/12 6/12
DIA = dot blot enzyme immunoassay; MIT = mouse inoculation test.suggesting that these animals were probably sacri-
ficed earlier in the course of the disease process. By
comparison to FAT, the specificity of this DIA was
found to be 100%. In this study, 15 animal brains (all
dogs) were partially putrefied. In spite of this, the
results obtained with these samples also showed
100% concordance, suggesting that DIA can also be
used in partially putrefied brain samples.
Ante-mortem clinical samples
Twelve saliva and 12 CSF samples were tested from
patients whose diagnosis was confirmed at autopsy
by direct FAT on their respective brain tissue sam-
ples. Of these, five CSF and four saliva samples were
positive by both DIA and MIT, whereas two saliva
samples and one CSF sample were positive only by
MIT (Table 2). The remaining six samples of saliva
and CSF were found to be negative by both the tests.
Therefore, the concordance of this procedure with
MIT is 83.3% for saliva and 91.6% for CSF. As with the
brain samples, no false negative results were
observed and therefore the specificity with clinical
samples is also 100%. However, the overall sensitiv-
ity of this procedure as an ante-mortem diagnostic
tool is quite low, about 33.3% in the case of saliva
and 43.3% for CSF samples.Discussion
The detection of viral antigens in various clinical
specimens such as stools, respiratory secretions and
serum using dot blot immunoassays has proved to be
very useful both for diagnosis and in epidemiological
studies.6—8 Use of this type of immunoassay in the
diagnosis of rabies has not found wide application.brain samples compared with fluorescent antibody test.
DIA+ FAT DIA FAT+ Concordance %
0/210 3/210 98.5%
0/10 0/10 100%
0/22 1/30 96.6%
0/16 0/16 100%
0/250 4/266 98.4%
use inoculation test with cerebrospinal fluid and saliva
DIA+ MIT DIA MIT+ Concordance %
0/16 2/12 83.3%
0/12 1/12 91.6%
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Figure 1 Dot blot immunoassay on a polyvinylidene difluoride membrane for the rapid diagnosis of rabies. BL = Blank;
PC = Positive control; NC = Negative control; Positive samples: S2, S6, S10 and S12; Negative samples: S1, S3, S4, S5, S7, S8, S9
and S11.As the World Health Organization is evolving various
strategies to control and eliminate human and ani-
mal rabies in Asian countries, diagnostic techniques
that can be easily applied in the field will provide atrue epidemiological picture.13 Further, most of the
animal bites in developing countries like India occur
in peripheral districts without laboratory facilities
to confirm the rabid status of the animal. Often, the
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tories for diagnosis and post-exposure treatment
instituted pending the test report, which may take
many days to weeks. Many of these post-exposure
treatments could be avoided if the rabid status of
the animal could be ruled out by the use of simple
tests that could be carried out at small peripheral
laboratories. Keeping this in mind, a direct dot blot
immunoassay has been developed and evaluated
against the gold standard FAT. The assay itself is a
simple procedure consisting of the application of the
brain homogenate (antigen) as a dot on the PVDF
membrane, followed by drying and subsequent
detection using biotinylated antinucleoprotein anti-
body and color development with DAB. The earlier
work carried out by Jayakumar et al. used similar
principles but they used antiserum to the whole
virus and nitrocellulose membrane for blotting14.
In order to further increase the specificity and
sensitivity of the test, the rabies nucleoprotein
antigen was purified, the antinucleoprotein anti-
body was raised and the antibody was biotinylated.
As the rabies nucleoprotein is the most abundant
viral antigen produced in the infected brain, this
rabies-specific antigen can be easily detected using
the specific antibody. The results of this study indi-
cate that there is a 97.6% concordance with the gold
standard FAT and the specificity of this test is 100%.
The test is rapid, does not require costly equipment
and the results can be observed by visual examina-
tion for the presence (positive) or absence (nega-
tive) of distinct dark brown spots. The only specific
reagent that is required is the biotinylated antinu-
cleocapsid antibody. This could be prepared in a
central reference laboratory and then supplied to
peripheral laboratories, which could then routinely
perform this test and diagnose rabies. This will not
only help in avoiding unnecessary post-exposure
treatments but also in performing epidemiological
surveys for the prevalence of rabies in animals in
specific geographic regions.
Another advantage of this test is that even par-
tially decomposed specimens could be tested, which
is not the case with FAT, as interpretation may be
difficult in the presence of non-specific fluores-
cence. This is in accordance with earlier results
obtained with other enzyme immunoassays such
as rapid rabies enzyme immunodiagnosis (RREID)
developed by Perrin et al.15
One disadvantage of this test seems to be the
occasional false negatives that can be encountered
if the animal is killed early in the disease process. In
such cases, increasing the concentration of brain
homogenate (from 10 to 20% or 30%) may yield
positive results. This aspect needs to be further
studied.Another aspect that needs to be evaluated is the
ability of this test to detect rabies antigen in clinical
specimens like saliva and CSF from patients with
suspected rabies encephalitis. Although majority of
patients inAsiancountriespresentwith typical clinical
features of furious rabies, including hydrophobia,
atypical presentation with ascending paralysis invol-
ving all the limbs and urinary bladder is not uncom-
mon. For instance, in this tertiary care specialized
hospital approximately five to seven cases of paralytic
rabies are admitted every year. Often the diagnosis is
confirmed only after autopsy. Many tests have been
advocated for ante-mortem diagnosis including the
much-publicized corneal test and frozen section skin
biopsy.16 However, our experience of these tests has
not been encouraging. In order to evaluate the detec-
tion of viral antigen in clinical specimens like CSF and
saliva as a means of ante-mortem diagnosis of human
rabies, these sampleswere testedbyDIAwithMITused
as a confirmatory test. Although there was good cor-
relationbetween the results ofDIAandMIT, theoverall
sensitivity of the technique when used with CSF or
salivawas lower thanwhenusedwithbrain specimens.
This is as expectedbecause thepresenceof thevirus in
theCSF of rabies patients is not a constant feature and
salivary secretion of the virus is intermittent, requir-
ing testing of several samples. As the specificity of this
test was 100%, even with clinical samples, a positive
result with this test will help the physician to establish
a definitive diagnosis of rabies ante-mortem and help
in theappropriatemanagementofnotonly thepatient
but also the close contacts.Conclusion
A simple, rapid, direct dot immunoassay has been
developed and evaluated for the detection of rabies
antigen in rabies-suspected animal brains. The test
has the potential to be used in field conditions, help-
ing not only the institution of timely post-exposure
rabies prophylaxis but also facilitating epidemiologi-
cal surveys for animal rabies in the region. However,
the utility of this technique for rapid ante-mortem
diagnosis of human rabiesis limited. This test is in the
process of being evaluated prospectively with other
tests recommended for ante-mortem diagnosis,
including thedetection of viral nucleic acid in clinical
specimens by PCR.Acknowledgements
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